Barclays Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price target lowered by Barclays from $56.00 to $42.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has an equal weight rating on the stock. Several other equities analysts have also recently commented on the stock. Truist Financial boosted their price […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price target lowered by Barclays from $56.00 to $42.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has an equal weight rating on the stock. Several other equities analysts have also recently commented on the stock. Truist Financial boosted their price […]
